CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
T-lymphoblastic Lymphoma|T-ALL
BIOLOGICAL: CAR-T
Safety: Incidence and severity of adverse events, Incidence and severity of adverse events, 28 days after infusion
Main research purposes:

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.

Secondary research purposes:

To preliminarily evaluate the efficacy, pharmacokinetics and pharmacodynamics of SENL101 in the treatment of patients with relapsed or refractory T-LBL/ALL.

Exploratory research purpose：

1. To explore the immunogenicity of SENL101；
2. T cell NK cell recovery time after treatment；